Effects of RAAS Inhibitors on Kidney Health in Dogs
Author Information
Author(s): Nasr Amirah, Lourenço Bianca N., Coleman Amanda E., Bartges Joseph W.
Primary Institution: University of Georgia, Athens, GA, United States
Hypothesis
Mean serum SDMA concentrations would be increased in dogs after 7 and 30 days of treatment with an orally administered RAASi.
Conclusion
Dogs with proteinuric CKD that received RAAS inhibitors experienced mild and inconsistent changes in serum SDMA, creatinine, and SUN concentrations.
Supporting Evidence
- Mean percentage change in SDMA was −4.8% at day 7 and −3.2% at day 30.
- Significant increases in creatinine and SUN were observed in dogs receiving RAASi alone.
- Significant decrease in mean SDMA was noted in dogs co-treated with amlodipine.
Takeaway
This study looked at how certain medications affect kidney health in dogs. It found that the medications caused small changes in kidney markers, but not as much as expected.
Methodology
This was a retrospective study using banked serum samples from 29 dogs with proteinuric CKD treated with enalapril or telmisartan, measuring serum SDMA, creatinine, and urea nitrogen concentrations before and after treatment.
Potential Biases
Potential bias due to the exclusion of dogs with significant increases in serum creatinine.
Limitations
The sample size within each group was small, and the study was retrospective, which may limit the generalizability of the findings.
Participant Demographics
Dogs were middle-aged to older, with a majority being female and non-azotemic; 89% were purebred.
Statistical Information
P-Value
0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website